DAPT, an orally active GSI, enhances CD8 + T cell cytotoxicity and pro-inflammatory cytokine secretion while reducing PD-1 expression in colorectal carcinoma patients [160]. The gene discussed is CD8A; the disease is colorectal carcinoma.